-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] On January 20th, the traditional Chinese medicine sector reappeared.
Among them, Tus Pharmaceuticals rose by more than 10%, Essence Pharmaceuticals rose by nearly 10%, Longjin Pharmaceutical rose by more than 6%, China Resources Sanjiu and Lingrui Pharmaceuticals , Longshenrongfa, etc.
rose more than 3%
.
In addition, there are also individual stocks such as Xinbang Pharmaceutical, Hansen Pharmaceutical, Guizhou Bailing and so on
.
TusPharm: up over 10% TusPharm's opening quotation was 9.
74 yuan, up 10.
0% as of 11:32, and the price limit has been closed, with a turnover of 78.
31 million and a turnover rate of 3.
07%
.
The current total market value is 2.
579 billion
.
On the news, on January 18, Tus Pharmaceutical announced that the company plans to increase the capital of Tus Bio with RMB 23.
5 million in cash, and Ningbo Yiduoduo plans to increase the capital to Tus Bio with RMB 1.
5 million in cash
.
After the completion of this capital increase, Tus Pharmaceuticals holds 90% of the shares of Tus Bio, and Ningbo Yiduoduo holds 10% of the shares of Tus Bio
.
According to the data, the business scope of Tus Pharmaceuticals includes sales of medical equipment; network information technology, system integration,
etc.
According to the third quarterly report of 2021, the company achieved a net profit of 39.
066 million yuan in the first nine months, a year-on-year increase of 102.
14% in net profit; revenue increased by 22.
54%
.
Essence Pharma: The increase is close to 10%.
Under the background of the hot concept of traditional Chinese medicine + pension, Essence Pharma, which has 13 boards in 20 days, still performed very well today.
As of 11:32, the increase was 9.
99%, the turnover was 734 million, and the turnover rate was 4.
24%.
.
The current total market value is 17.
391 billion
.
Some analysts believe that Essence Pharma focuses on three main aspects: First, Chinese medicine is the main focus.
The company's chemical drugs are mainly phenobarbital, phenylbutazone and fluorouracil, and pharmaceutical intermediates such as dioxane, among which phenobarbital.
It is the company's dominant product; Fluorouracil has passed the US FDA certification, and phenobarbital, fluorouracil, phenylbutazone and primidone have passed the European COS certification; the main drugs under development include PD-L1, betatinib, and the subsidiary Kingsley L-Levo Pantoprazole sodium, etc.
; chemical raw materials and intermediates in 2019 were 305 million yuan, accounting for 26.
3% of the main business; secondly, the product Zhengchaihuyin granules was very effective for flu symptoms such as exogenous cold onset, fever and aversion to cold, etc.
Good inhibitory effect; third, the holding subsidiary Senxuan Pharmaceutical (holding 72.
31%) is the main domestic supplier of ritonavir intermediates
.
According to the third quarterly report of 2021, the company achieved a net profit of 128 million yuan from January to September, a year-on-year increase of 26.
32% in net profit; revenue increased by 4.
69%
.
Longjin Pharmaceutical: up more than 6% Longjin Pharmaceutical has also received much market attention recently, and has closed the price limit for many times
.
As of 11:32, an increase of 6.
33%, the turnover was 788 million, and the turnover rate was 10.
24%
.
The current total market value is 7.
870 billion
.
According to the third quarterly report of 2021, the company achieved a net profit of 6.
5727 million yuan from January to September, a year-on-year increase of 187.
68% in net profit; revenue increased by 261.
23%
.
Longjin Pharmaceutical's financing and securities lending information shows that on January 18, 2022, the net repayment of financing was 40.
9433 million yuan; the financing balance was 135 million yuan, a decrease of 23.
26% from the previous day
.
In terms of financing, 35.
3855 million yuan was purchased on the same day, 76.
3288 million yuan was repaid, and the net repayment was 40.
9433 million yuan
.
In terms of securities lending, 0 shares were sold and 0 shares were repaid by securities lending.
The balance of securities lending was 339,100 shares, and the balance of securities lending was 6.
8261 million yuan.
.
The balance of margin financing and securities lending totaled 142 million yuan
.
On the news, the policy continues to bring benefits to the traditional Chinese medicine industry
.
Not long ago, the National Medical Insurance Administration and other two departments issued guidance on medical insurance supporting the inheritance, innovation and development of traditional Chinese medicine
.
The document proposes that qualified traditional Chinese medicine (including integrated traditional Chinese and Western medicine, minority medicine) medical institutions and traditional Chinese medicine retail pharmacies should be included in the management of medical insurance fixed-point agreements in a timely manner
.
The designated TCM medical institutions that carry out Internet diagnosis and treatment shall, in accordance with the regulations, sign supplementary agreements with the medical insurance agencies in the overall planning area, and include the "Internet +" TCM services provided by them into the scope of medical insurance payment
.
According to regulations, qualified Chinese herbal decoction pieces, proprietary Chinese medicines, and Chinese herbal medicine preparations in medical institutions will be included in the medical insurance drug list
.
Among them, Tus Pharmaceuticals rose by more than 10%, Essence Pharmaceuticals rose by nearly 10%, Longjin Pharmaceutical rose by more than 6%, China Resources Sanjiu and Lingrui Pharmaceuticals , Longshenrongfa, etc.
rose more than 3%
.
In addition, there are also individual stocks such as Xinbang Pharmaceutical, Hansen Pharmaceutical, Guizhou Bailing and so on
.
TusPharm: up over 10% TusPharm's opening quotation was 9.
74 yuan, up 10.
0% as of 11:32, and the price limit has been closed, with a turnover of 78.
31 million and a turnover rate of 3.
07%
.
The current total market value is 2.
579 billion
.
On the news, on January 18, Tus Pharmaceutical announced that the company plans to increase the capital of Tus Bio with RMB 23.
5 million in cash, and Ningbo Yiduoduo plans to increase the capital to Tus Bio with RMB 1.
5 million in cash
.
After the completion of this capital increase, Tus Pharmaceuticals holds 90% of the shares of Tus Bio, and Ningbo Yiduoduo holds 10% of the shares of Tus Bio
.
According to the data, the business scope of Tus Pharmaceuticals includes sales of medical equipment; network information technology, system integration,
etc.
According to the third quarterly report of 2021, the company achieved a net profit of 39.
066 million yuan in the first nine months, a year-on-year increase of 102.
14% in net profit; revenue increased by 22.
54%
.
Essence Pharma: The increase is close to 10%.
Under the background of the hot concept of traditional Chinese medicine + pension, Essence Pharma, which has 13 boards in 20 days, still performed very well today.
As of 11:32, the increase was 9.
99%, the turnover was 734 million, and the turnover rate was 4.
24%.
.
The current total market value is 17.
391 billion
.
Some analysts believe that Essence Pharma focuses on three main aspects: First, Chinese medicine is the main focus.
The company's chemical drugs are mainly phenobarbital, phenylbutazone and fluorouracil, and pharmaceutical intermediates such as dioxane, among which phenobarbital.
It is the company's dominant product; Fluorouracil has passed the US FDA certification, and phenobarbital, fluorouracil, phenylbutazone and primidone have passed the European COS certification; the main drugs under development include PD-L1, betatinib, and the subsidiary Kingsley L-Levo Pantoprazole sodium, etc.
; chemical raw materials and intermediates in 2019 were 305 million yuan, accounting for 26.
3% of the main business; secondly, the product Zhengchaihuyin granules was very effective for flu symptoms such as exogenous cold onset, fever and aversion to cold, etc.
Good inhibitory effect; third, the holding subsidiary Senxuan Pharmaceutical (holding 72.
31%) is the main domestic supplier of ritonavir intermediates
.
According to the third quarterly report of 2021, the company achieved a net profit of 128 million yuan from January to September, a year-on-year increase of 26.
32% in net profit; revenue increased by 4.
69%
.
Longjin Pharmaceutical: up more than 6% Longjin Pharmaceutical has also received much market attention recently, and has closed the price limit for many times
.
As of 11:32, an increase of 6.
33%, the turnover was 788 million, and the turnover rate was 10.
24%
.
The current total market value is 7.
870 billion
.
According to the third quarterly report of 2021, the company achieved a net profit of 6.
5727 million yuan from January to September, a year-on-year increase of 187.
68% in net profit; revenue increased by 261.
23%
.
Longjin Pharmaceutical's financing and securities lending information shows that on January 18, 2022, the net repayment of financing was 40.
9433 million yuan; the financing balance was 135 million yuan, a decrease of 23.
26% from the previous day
.
In terms of financing, 35.
3855 million yuan was purchased on the same day, 76.
3288 million yuan was repaid, and the net repayment was 40.
9433 million yuan
.
In terms of securities lending, 0 shares were sold and 0 shares were repaid by securities lending.
The balance of securities lending was 339,100 shares, and the balance of securities lending was 6.
8261 million yuan.
.
The balance of margin financing and securities lending totaled 142 million yuan
.
On the news, the policy continues to bring benefits to the traditional Chinese medicine industry
.
Not long ago, the National Medical Insurance Administration and other two departments issued guidance on medical insurance supporting the inheritance, innovation and development of traditional Chinese medicine
.
The document proposes that qualified traditional Chinese medicine (including integrated traditional Chinese and Western medicine, minority medicine) medical institutions and traditional Chinese medicine retail pharmacies should be included in the management of medical insurance fixed-point agreements in a timely manner
.
The designated TCM medical institutions that carry out Internet diagnosis and treatment shall, in accordance with the regulations, sign supplementary agreements with the medical insurance agencies in the overall planning area, and include the "Internet +" TCM services provided by them into the scope of medical insurance payment
.
According to regulations, qualified Chinese herbal decoction pieces, proprietary Chinese medicines, and Chinese herbal medicine preparations in medical institutions will be included in the medical insurance drug list
.
